Rapid Dose Therapeutics Corp (TSE:DOSE)
:DOSE
DOSE Stock Chart & Stats
C$0.14
C$0.02(6.67%)
At close: 4:00 PM EST
C$0.14
C$0.02(6.67%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.24
Previous CloseN/A
Volume31.00K
Average Volume (3M)36.09K
Market Cap
C$15.83M
Enterprise ValueC$24.00M
Total Cash (Recent Filing)C$109.16K
Total Debt (Recent Filing)C$8.28M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Jun 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding131,886,760
10 Day Avg. Volume35,351
30 Day Avg. Volume36,089
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)-5.82
Price to Sales (P/S)18.01
P/FCF Ratio-8.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Oral Thin‑film PlatformThe company’s owned quick-dissolve oral film technology is a durable competitive asset. As an enabling delivery platform it can generate formulation and licensing revenue, create switching costs for partners, and support cross-market applications in pharma and consumer health over multiple product cycles.
Consistent Revenue ImprovementRevenue has been rising modestly and shows improved top-line traction versus prior years. For a platform company, steady revenue growth indicates increasing partner adoption and repeat formulations, which supports a pathway to scale if margins and commercial reach continue developing.
Improving Free Cash Flow TrendFree cash flow improvement signals management has begun to reduce cash burn or improve operating efficiency. While FCF remains negative, a sustained improvement trend can materially lower funding needs and extend runway, making execution on partnerships and commercialization more viable over months.
Bears Say
Negative Shareholders' Equity And LeverageA deficit equity position combined with material debt raises solvency and liquidity risk. This structural balance-sheet weakness limits financial flexibility, increases default or covenant risk, and makes future funding more dilutive or expensive, constraining long-term investment capacity.
Ongoing Cash BurnPersistent negative operating and free cash flow mean the company remains dependent on external capital. Continued cash burn can force repeated equity or debt raises, diluting shareholders or increasing leverage, and may disrupt multi‑period commercialization plans if funding windows tighten.
Deep Operating Losses & Weak MarginsVery negative operating and net margins show the business has not yet reached profitable scale; low gross margin limits upside from revenue growth. Structural profitability shortfalls require sustained margin improvement or major revenue inflection to achieve long‑term self‑sufficiency.
Rapid Dose Therapeutics Corp News
DOSE FAQ
What was Rapid Dose Therapeutics Corp’s price range in the past 12 months?
Rapid Dose Therapeutics Corp lowest stock price was C$0.09 and its highest was C$0.24 in the past 12 months.
What is Rapid Dose Therapeutics Corp’s market cap?
Rapid Dose Therapeutics Corp’s market cap is C$15.83M.
When is Rapid Dose Therapeutics Corp’s upcoming earnings report date?
Rapid Dose Therapeutics Corp’s upcoming earnings report date is Jun 26, 2026 which is in 83 days.
How were Rapid Dose Therapeutics Corp’s earnings last quarter?
Rapid Dose Therapeutics Corp released its earnings results on Jan 29, 2026. The company reported -C$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.009.
Is Rapid Dose Therapeutics Corp overvalued?
According to Wall Street analysts Rapid Dose Therapeutics Corp’s price is currently Overvalued.
Does Rapid Dose Therapeutics Corp pay dividends?
Rapid Dose Therapeutics Corp does not currently pay dividends.
What is Rapid Dose Therapeutics Corp’s EPS estimate?
Rapid Dose Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapid Dose Therapeutics Corp have?
Rapid Dose Therapeutics Corp has 131,886,760 shares outstanding.
What happened to Rapid Dose Therapeutics Corp’s price movement after its last earnings report?
Rapid Dose Therapeutics Corp reported an EPS of -C$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Rapid Dose Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:DOSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.
Technical Analysis
BriaCell Therapeutics
―
Hemostemix
―
Britannia Life Sciences Inc
―
Sirona Biochem
―
Telescope Innovations Corp
―
Options Prices
Currently, No data available
---